CRSP: CRISPR Market Capitalization to Book Value Ratio
CRISPR Therapeutics AG (CRSP) is implementing AI algorithms and robotics to automate precise genome editing, eliminating manual labor. This price action chart on GURU.Markets captured the 2.86 metric. However, sanctions and political fragmentation are hindering the delivery of biomaterials and international scientific exchange. The company is currently deploying a network of automated stations for 24/7 modification screening, which accelerates the launch of new products.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_CRSP_-_CRISPR-Therapeutics-AG_-_Capitalization-to-Book-Value-Ratio "CRSP: crisprtx.com Market Value to Book Value Ratio 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company CRISPR Therapeutics Inc (CRSP)
- market value and analyst target forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Capital CRISPR Therapeutics AG|CRSP - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity CRISPR Therapeutics Corp|CRSP - Aggregate Debt Obligations|Debts to Book Capitalization CRISPR Therapeutics Corp|CRSP - Long-Term Debt Volume|Company Short-Term Debt CRISPR Therapeutics|Quick Liquidity crisprtx.com
- earnings and market multiples details:
Summary company analytics:CRISPR Therapeutics AG - CRSP
This multiple determines investment reliability by comparing the market value of the business with its net assets to identify whether shares are overvalued or undervalued. By analyzing the historical P/BV ratio of CRISPR Therapeutics AG (CRSP), an investor assesses the premium to equity, which for CRISPR Therapeutics AG (CRSP) is justified by the high value of gene therapy patents and significant licensing revenues from global pharma partners.
Competitors of CRISPR Therapeutics AG (CRSP)
Tempus Labs (TEM) - Market Value to Book Value Ratio|Market Capitalization to Net Assets QGEN (qiagen.com)|IONS (Ionis) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio RGEN (Repligen Corp)|Market Value to Book Value Ratio Avidity (RNA)|GeneDx Corp - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio RARE (Ultragenyx Pharmaceutical)|Market Capitalization to Book Value Ratio beamtx.com BEAM|Sarepta - Market Capitalization to Book Value Ratio|Twist Bioscience Inc (TWST) - Market Cap to Net Assets Ratio|10x Genomics Corp (TXG) - Market Value to Book Value Ratio|Intellia Corp - Market Value to Book Value|STOK (Stoke Therapeutics) - Market Capitalization to Book Value Ratio|biolifesolutions.com (BLFS) - Market Capitalization to Book Value|Market Value to Book Value Ratio Wave Life Sciences Ltd. (WVE)|Market Capitalization to Book Value Maze Therapeutics, Inc.|Market Value to Book Value Ratio Sionna Pharma SION|PRME (Prime Medicine Bio) - Market Capitalization to Net Assets|TSHA - Market Value to Book Value Ratio|Market Value to Book Value QURE (uniqure.com)|MGTX (MeiraGTx) - Market Cap to Net Assets Ratio|REGENXBIO Inc - Market Value to Book Value|Market Cap to Net Assets Ratio SLDB|OCGN (Ocugen Pharma) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio PACB|BNTC (benitec.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio DSGN (Design Therapeutics, Inc.)|Rocket Pharma (RCKT) - Market-to-Book Ratio|FDMT - Market Value to Book Value Ratio|Market Value to Book Value LXEO (Lexeo Therapeutics)|KRRO: Market Capitalization to Book Value Ratio|editasmedicine.com (EDIT) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Silence Therapeutics plc|ProQR Therapeutics NV - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio CDXS|SGMO - Market-to-Book Ratio|Nautilus Bio - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio metagenomi.co MGX|DTIL: Market Cap to Net Assets Ratio|Generation Bio Co. - Market Cap to Book Value Multiple|BOLD: Market Capitalization to Book Value Ratio|XCUR - Market Capitalization to Book Value|IMNN (Imunon Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio RXi Pharmaceuticals (PHIO)|Market Value to Book Value Ratio Mustang Bio, Inc. (MBIO)|Market Capitalization to Book Value transcodetherapeutics.com|Bionano Genomics - Market Cap to Net Assets Ratio|Market Value to Book Value APDN|bluebird bio, Inc. - Market Capitalization to Book Value Ratio|IPA - Market Capitalization to Book Value Ratio|OMGA: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Singular Genomics Systems, Inc. OMIC|RGLS (Regulus Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Syros Pharmaceuticals, Inc (SYRS)|Market Value to Book Value Ratio Telesis Bio, Inc. (TBIO)|TCON (traconpharma.com) - Market Value to Book Value|Market Value to Book Value Ratio Unity Biotechnology, Inc. UBX